Haemonetics delivered a clean earnings beat on August 6 and the Street responded fast — target prices moved sharply higher across the board, with the stock now sitting at $87.84 and up 17% over the past month.
The analyst reaction tells the clearest story this week. Multiple firms raised targets within 24 hours of the print. JP Morgan's Allen Gong lifted his target from $62 to $86, while Citigroup's Joanne Wuensch moved from $79 to $92 — both keeping Neutral ratings, but the magnitude of the moves signals a meaningful upward revision to the fundamental model. BTIG, carrying a Buy, raised to $96 from $84. The consensus mean target now sits at $94.70, leaving roughly 8% implied upside from current levels. That's a modest gap, but the direction of travel has been consistently upward: Mizuho lifted to $90 in mid-July, Bank of America upgraded to Buy in May. The tone is constructive, even if the neutrals aren't fully convinced the stock has room to run from here.
The bull case centres on the MedSurg pivot — Haemonetics has been shifting revenue toward Blood Management and Interventional Technologies through acquisitions, and bulls argue new product launches and plasma segment recovery can drive best-in-class MedTech margins. Bears counter that Interventional Technologies has stumbled commercially, blood center competition is intensifying, and hospital segment growth has disappointed. The PE of 15.6x and EV/EBITDA of 10.4x are neither cheap nor demanding for a company still working through a business mix transition. Forward earnings expectations rank well above median on a 12-month basis (79th percentile), but near-term EPS momentum has softened — the 30-day and 90-day readings both sit around the 28th to 30th percentile — suggesting the upgrade cycle has run slightly ahead of estimates.
Positioning is about as relaxed as it gets for a stock with 5.4% of float short. Borrow availability is extraordinarily loose at nearly 5,000% — there are roughly 27.7 million shares available to lend against 2.5 million currently borrowed. Cost to borrow has fallen sharply, down 32% on the week to just 0.37%, the lowest reading in the 30-day history. Short interest itself has dropped 4.3% on the week and nearly 10% over the past month, a steady bleed that accelerated after the earnings release. The ORTEX short score has drifted lower too, easing from around 40.7 a week ago to 39.6 — consistent with a stock where the marginal short is heading for the exit. Where sentiment has shifted is in options: the put/call ratio jumped from 0.16 pre-earnings to 0.33 post-print, now running about 1.4 standard deviations above its 20-day mean of 0.22. That's a notable rotation — call-side euphoria ahead of the number has given way to some hedging now that the catalyst is behind us.
Peers had a broadly positive week in medtech. TMDX gained nearly 10% and SIBN rose 4.8%, while GMED and SYK added around 4-5%. HAE's 2.7% weekly gain looks modest in that context, though the prior week's surge of over 8% means the stock came into this period already ahead of the pack.
The stock has no next earnings date confirmed yet — what to watch now is whether the Street's neutrals begin upgrading in earnest as the Interventional Technologies narrative stabilises, or whether the gap between the $87.84 close and BTIG's $96 Buy target narrows through price action rather than through further estimate revision.
See the live data behind this article on ORTEX.
Open HAE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
